Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease

Back

ESC Professional Premium Access

Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease

Session: Risk assessment in pulmonary hypertension: still a hot topic

Topic: Pharmacotherapy

Speaker: Doctor R. Luna (Barcelona, ES)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Raquel Luna

Hospital Clinic of Barcelona, Barcelona (Spain)

0 follower

6 more presentations in this session

Comprehensive risk assessment in patients with pulmonary arterial hypertension referred for lung transplantation: a single-center experience

Speaker: Doctor S. Ishii (Tokyo, JP)

REVEAL Score performance in patients with WHO Group 2 pulmonary hypertension

Speaker: Doctor D. Sharp Dimitri (Cincinnati, US)

Analysis of prognostic predictors and differences between subgroups of pulmonary arterial hypertension associated with portal hypertension and HIV infection

Speaker: Doctor R. Bertozzi (Cesena, IT)

Applicability of the 3-Strata ESC/ERS risk model at baseline in pulmonary veno-occlusive disease

Speaker: Doctor A. Cruz Utrilla (Madrid, ES)

Phenotype and outcome correlates of high dose loop diuretics in type 1 pulmonary hypertension

Speaker: Doctor D. Barbisan (Treviso, IT)

Access the full session

Risk assessment in pulmonary hypertension: still a hot topic

Speakers: Doctor R. Luna, Doctor S. Ishii, Doctor D. Sharp Dimitri, Doctor R. Bertozzi, Doctor A. Cruz Utrilla...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources